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Abstract
Development of new, anti-metastatic drugs from natural products has been substantially 
constrained by the lack of a reliable in vitro screening system. Such a system should ideally mimic 
the native, three-dimensional (3D) tumor microenvironment involving different cell types and 
allow quantitative analysis of cell behavior critical for metastasis. These requirements are largely 
unmet in the current model systems, leading to poor predictability of the in vitro collected data for 
in vivo trials, as well as prevailing inconsistency among different in vitro tests. In the present 
study, we report application of a 3D, microfluidic device for validation of the anti-metastatic 
effects of twelve natural compounds. This system supports co-culture of endothelial and cancer 
cells in their native 3D morphology as in the tumor microenvironment, and provides real-time 
monitoring of the cells treated with each compound. We found that three compounds, namely 
sanguinarine, nitidine, and resveratrol, exhibited significant anti-metastatic or anti-angiogenic 
effects. Each compound was further examined for its respective activity with separate 
conventional biological assays, and the outcomes were in agreement with the findings collected 
from the microfluidic system. In summary, we recommend use of this biomimetic model system 
as a new engineering tool for high-throughput evaluation of more diverse natural compounds with 
varying anti-cancer potentials.
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Metastasis is the spreading of cancer from its primary site to other parts of the body.1 It is 
the late, critical stage that accounts for most cancer deaths, and is a main target for the 
development of anti-cancer drugs.1 Over the last two decades, a number of compounds 
derived from natural resources have shown preliminary anti-metastatic potential when tested 
in cell culture.2 However, the drug efficacy data collected from these studies have largely 
proved difficult to reproduce in other in vitro systems or to predict further in vivo tests, 
providing little guidance for downstream investigations including animal studies. Moreover, 
investigations into the exact mechanisms of these natural compounds appear obscure or 
inconsistent among one another. Typical examples include studies of berberine and 
evodiamine, two natural alkaloids with extensive reports for their anti-metastatic function in 
vitro.3 The former’s effect was attributed to a long, confusing list of mechanisms, involving 
inhibition of Akt-nuclear factor kappa B (NF-kappa B)-MMP2/9 cascade3a, activation of 
AMP-activated protein kinase (AMPK)4 and blocking of heparanase expression,5 among 
many others. The latter was suggested to inhibit metastasis in cultured cancer cells,3c–e but 
was reported elsewhere to effectively increase the secretion of interleukin-8 (IL-8),6 a 
cytokine well-evidenced to promote adhesion, migration and invasion of cancer cells.7 As a 
result, very few of these molecules could finally reach clinical trials.
Among the reasons for the above inconsistencies is the lack of a reliable in vitro model for 
anti-metastatic screening. Metastasis involves dynamic interaction of several cell types 
residing in a complex, three-dimensional (3D) microenvironment, notably including tumor 
cells and endothelial cells.1b Therefore, in the screening system, it is essential to maintain 
the 3D, native morphology of cells, and it is senseless to neglect the crosstalk between 
endothelial cells and tumor cells. Nevertheless, most present models for in vitro screening 
are simply carcinoma monolayer cultivated in the two-dimensional (2D) tissue-culture 
plastics (TCPs), without taking into consideration communications between, and proper 
morphology of, different cell types. Although co-culture techniques such as the Transwell 
device have increasingly been used in the recent years, they only achieved to physically 
culture two cell types in one well yet still fail to mimic the 3D morphology – and hence the 
behavior and phenotypes – of various cells involved. Furthermore, hardly any current model 
provides real-time monitoring of the behavior of the two (or more) cells types and especially 
their dynamic interactions, which are crucial given the ample evidence that secretion of one 
cell type highly influences and even ‘educates’ the others.8 All these concerns are providing 
answers to the inconsistent performances of the natural compounds – their effect on cancer 
cells in two-dimensional (2D) monolayer may be resisted by the same cells in their native, 
3D organization in vivo, or their inhibition of cancer cell spreading was probably 
antagonized by cytokines released from endothelium. Obviously, new models that closely 
mimic the genuine tumor microenvironment and that can recapitulate part of the complex 
metastatic process are in high demand.
In our previous study, we reported a microfluidics-based model that highly recapitulates 
tumor microenvironment by co-culturing endothelial cells in 3D collagen gels and cancer 
cells formed into 3D spheroids9. Model drugs such as Gefitinib (AstraZeneca, Food and 
Drug Administration-approved) and Masitinib (AB Science, currently undergoing Phase III 
clinical trial), which had inhibitory effects on epithelial-mesenchymal transition (EMT), a 
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key mechanism of metastasis, were applied to the device followed by real-time monitoring 
and quantitative analysis. The outcomes were not only consistent with findings based on 
conventional in vitro and in vivo platforms, but also validated the effects of those drugs in 
inhibiting EMT and thus metastasis with precise range of effective dose and dynamic 
monitoring throughout the investigation. This kind of tools would be particularly needed for 
accurate evaluation of natural products. Therefore, in this study, we hypothesized that using 
such a bio-mimicking system could help to validate the anti-metastatic effects of natural 
compounds under the specific, co-cultural condition.
We first prepared the microfluidics device. Our principle of design was to introduce 
collagen gel into particular zones in the device. Endothelial cells should adhere to this gel, 
spread on the gel, and form an intact endothelial layer. Then, in the same chamber pre-
prepared cancer-cell spheroids would be added and co-cultured with the endothelial cells, so 
as to create a physiologically relevant microenvironment. We fabricated the device using 
polydimethylsiloxane (PDMS) bound to a glass coverslip to form a transparent chamber; 
during the process, the PDMS replicas were the negative image of the positive relief 
structure of patterned wafer made by soft lithography. The entire fabrication followed our 
previous protocol9 with minor modification in device channels in order to better visualize 
the morphology of the endothelial layer. As discussed later, we would particularly 
investigate the influence of different compounds on the human umbilical vein endothelial 
cells (HUVECs). As illustrated in Figure 1A, we added in one channel collagen solution 
(Type I, rat tail, BD Singapore) which, after gelation, supported the adhesion of endothelial 
cells (HUVECs, Lonza, Switzerland). Human lung carcinoma cell line A549 (ATCC, USA, 
CCL-185) stably expressing H2B-mCherry (pH2B-mCherry_IRES_puro2, Addgene® 
Plasmid 21045, USA), pre-generated through FuGENE 6 transfection (Roche, Singapore), 
puromycin selection, and FACS sorting, were cultured to form spheroids (40–100 μm in 
diameter) as described before. These spheroids were collected and mixed in a pre-optimized 
collagen buffer and pipetted into the designated channel carefully to avoid spillage to the 
adjacent channel. The average distance between endothelial layer and cancer spheroids 
defines that in the typical tumor microenvironment which allows sufficient cell-cell 
communications. The secretion of HUVECs could diffuse into the collagen matrix, along 
with drug molecules upon the formation of an intact endothelial monolayer. A sample 
photograph of fluorescently stained cells in this device is shown in Figure 1B.
We tested 12 natural compounds in this system (Figure 1C). We picked them up from a 
large number of candidates for two reasons – i) they have been reported to inhibit metastasis 
in vitro, and ii) they are representatives for two common structural families of natural 
products. Any validated bioactivity with these molecules may provide information for study 
of other compounds in the same categories. Compounds 1 to 6, namely matrine10, 
sanguinarine11, harmine12, nitidine13, berberine3a, b and evodiamine3c, are alkaloids. 
Compounds 7 to 12, which are resveratrol14, epigallocatechin gallate (EGCG)15, 
curcumin16, quercetin17, catechin18 and gallic acid19, respectively, belong to the polyphenol 
class. After consulting literature for the half maximal inhibitory concentration (IC50) of each 
compound against A549 or similar cancer cell lines in 2D condition (Supplementary Table 
1), we set a working concentration of 10 μM for Compounds 2 – 8, 50 μM for Compounds 9 
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– 12, and 100 μM for Compound 1. The compounds were applied to the endothelial channel, 
resembling the real process of drug diffusion across the capillary vessel in the circulating 
system. Before spheroid seeding, it was necessary to double check the devices one by one, 
in order to confirm the endothelial cells were spreading well and forming an intact layer. 
After spheroid seeding, we needed to check again to ensure both cell types were in their 
proper morphology..
Two of the twelve tested molecules, Compounds 4 and 7, significantly inhibited metastasis, 
as revealed by the morphology of A549 spheroids taken at 0 and 36 hours (Figure 2A) and 
the subsequent quantification of the dispersion (Figure 2B). In brief, for a specific spheroid, 
we first counted the number of cell nuclei, and then calculated the dispersion by using the 
Imaris 6.0 software (Bitplane), which generated a 3D histogram of nuclei distribution and 
helped us figure out the spheroid center (Xc, Yc, Zc) as well as the special coordinates of all 
nuclei (Xn, Yn, Zn). We next determined the standard deviation of each nucleus from the 
spheroid center (Δ, of a given spheroid). In doing so, we could evaluate the efficacy of each 
compound by calculating the normalized dispersion (Δ/Δ0), where Δ and Δ0 (at 0 h) must be 
generated from the same device.
Compound 4, or nitidine, almost completely abolished the dispersion of the spheroids, 
apparently killing the cancer cells, which remains further verification in 2D cultures. In 
comparison, Compound 7, resveratrol, was less strong yet convincingly effective. It 
inhibited the dispersion to ~ 60% of blank control. We further tested this compound at 10, 
50, 100 and 500 μM, and found that its dose dependency was less obvious at the range 
between 10 and 100 than from 100 to 500 μM (Figure 2C). Meanwhile in the endothelial 
channel, Compound 2, sanguinarine, was notable to be the only compound that drastically 
disrupted endothelial cell layer, according to cell morphology observation and live cell 
staining (Figure 2D). We assumed that Compound 2 had inhibitory effects specifically on 
endothelial cells, and it would be worth evaluating its anti-angiogenic potential. Apart from 
these three molecules, all other samples did not show statistically significant inhibition of 
spheroids dispersion or any obvious influence on endothelial cells. Although it was 
inappropriate to exclude their anti-metastatic or anti-angiogenic potential at all purely based 
on these tests, we do not recommend set priority of further evaluation on these 9 
compounds. Instead, we focused on Compounds 2, 4, and 7, whose interesting performance 
in the device motivated us to pick them up for further exploration in cultured plates.
We examined the cytotoxicity of Compound 2 on the two cell types cultured on TCPS with 
MTT assay. It was shown that HUVECs were more sensitive than A549 to this molecule at a 
lower dose (Figure 3A), which was consistent with our finding in the microfluidic device. 
However, Compound 2 at a higher dose of 5.44 μM, which was still lower than the tested 
dose in the device, almost completely killed both cell types, revealing the A549 cells were 
more sensitive to the drug in 2D monolayer than in 3D spheroids. We further examined its 
anti-angiogenic potential with tube formation assay on Matrigel (BD Bioscience, USA) 
supplemented with basic fibroblast growth factor (bFGF). After 8 h of treatment, compound 
2 could effectively inhibit tube formation at a concentration as low as 0.68 μM (~35% 
inhibition) and abolish all capillary-like tubes at 2.72 μM (Figure 3B). Hence, our findings 
both in and out of the device validated the anti-angiogenic effects of sanguinarine20, and for 
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the first time recommended a relatively lower concentration, 2.72 μM, for future evaluation 
of specific, anti-angiogenic compounds. At this concentration, the compound showed strong 
anti-angiogenic effects but low toxicity to A549 cells. On the contrary, several other 
compounds, including Compounds 3 (harmine),12 4 (nitidine),21 5 (berberine),22 7 
(resveratrol),23 10 (quercetin)24 and 12 (gallic acid),25 have been reported to be anti-
angiogenic in conventional cultures but failed to be validated in this co-culture system, 
though in this study we had chosen a concentration for each compound that is close to its 
own IC50 against HUVECs.
Compound 4 was tested at a wide range of concentration (1.63 to 26.05 μM) for its 
cytotoxicity, showing moderate inhibition on the viability of both cell types (Figure 4A). Its 
effect on A549 cells in monolayer appeared relatively mild as compared with that in the 
device. However, this might be due to the different cell behavior in 2D and 3D. As such, we 
generated the A549 spheroids again on polystyrene surface treated with 0.2% pluronic 
(Pluronic F108, BASF) for 4 days.26 Live/Dead staining indicated that the cell viability was 
extremely decreased by the treatment of Compound 4 (Figure 4B), which was consistent 
with the finding in the device and confirmed our assumption that these cancer cells had 
distinct sensitivity in 2D and in 3D organization. Furthermore, because this molecule was 
reported to induce cell death via inhibition of topoisomerase inhibitor, we examined how it 
affected topoisomerase I in cleaving plasmid DNA. Agarose gel electrophoresis clearly 
indicated that nitidine in all three tested concentrations (13, 26 and 52 μM) could unwind the 
supercoiled DNA, and the intensity of ‘relaxed’ DNA appeared to have a positive 
correlation with the compound dose (Figure 4C). Therefore, we suggest that Compound 4, 
regardless of its effects against metastasis, is effective in inducing cell apoptosis via 
inhibition of topoisomerase, which may be the starting point for future trials aimed at 
understanding the cellular mechanism of nitidine.
We next evaluated the anti-metastatic effect of Compound 7. This compound was of 
minimal toxicity to either cell type even at a considerably high concentration (109.53 μM for 
HUVECs and 219.07 for A549, respectively) (Figure 5A), but its inhibitory effect on the 
migration of A549 cancer cells was proved with scratch wound assay, followed by 
morphology observation (Figure 5B) and measurement of the average width between the 
two edges of each wound (Figure 5C). The average migration rate of PMA-challenged cells, 
which had been stimulated from 1.82 to 3.97 μm per hour, was effectively decreased to 3.38 
and a remarkable 1.77 μm per hour by resveratrol at the doses of 13.5 μM and 27 μM, 
respectively (Supplementary Table 2, with the calculation method). Such findings, in 
combination with the observations in the device, highlight that this compound possesses 
both potent anti-metastatic activity and minimal cytotoxicity at a very reasonable dose. 
Moreover, we speculate that its activity is associated with inhibition of EMT in cancer cells, 
according to the previous application of this platform.9 However, extensive experiments 
including staining of specific epithelial markers (such as E-cadherin)27 and mesenchymal 
markers (such as vimentin)28 are required before making further conclusion.
As presented, we have picked up three compounds – sanguinarine, nitidine and resveratrol – 
for their intriguing performance in the microfluidic system, and verified their different 
activities accordingly with tailor-made experiments out of device. For each compound, the 
Niu et al. Page 5
Mol Pharm. Author manuscript; available in PMC 2015 July 07.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
good correlation between its on- and off-chip performances was of major interest to us. As a 
drug screening platform in general, this system has shown potential to be a reliable and 
efficient tool for high-throughput compound screening. As an anti-metastatic model, its 
recapitulation of native microenvironment and real-time quantitative analysis provide 
reliable information taking into consideration of various biochemical and biophysical factors 
such as cell-cell communication, cytokine diffusion and/or cell morphology. Meanwhile, for 
the other nine compounds, it is neither the conclusion nor the aim of this study to assume 
that these molecules have no anti-metastatic effect. They failed to outperform Compounds 2, 
4 and 7 at the given dose (though having taken reference from literature about their IC50) to 
a specific cell line in this particular system, and were therefore not prioritized for the 
subsequent cell biology tests. However, they might be potent to different cancer cells via 
different mechanisms in another system, which requires fine tuning to the current device to 
introduce new biological microenvironment. Fortunately, the present microfluidic device is 
an open platform, readily fabricated with well-established techniques and conveniently 
adjustable to create different cell conditions.29 We are confident in preparation of new, on-
demand systems for validation of diverse natural molecules with specific therapeutic 
potentials.
To summarize, we have for the first time validated the anti-metastatic effects of natural 
compounds in an engineered platform. This 3D, microfluidics based system mimicking 
tumor microenvironment allows quantitative monitoring of endothelial and cancer cells in 
their native 3D organization. Of the selected 12 molecules, three compounds exhibited 
interesting but different activities within the given dose range, which were further verified 
with separate assays performed out of the device. Such findings may provide important 
insights on selection of biological targets and models in future, comprehensive 
investigations. More specifically, we would recommend testing Compound 2 for its anti-
angiogenic potential in relevant models, exploring Compound 4 for its exact mechanism of 
inducing apoptosis, as well as trialing Compound 7 as a potent inhibitor of EMT in various 
cancer models in vivo.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(A) Schematic illustration of the engineered microfluidic system for compound screening. 
Endothelial cells and cancer cell spheroids are applied to separate channels and co-cultured 
in their native 3D morphology in the tumor microenvironment. The device chamber is 
designed to allow diffusion of drugs and cell secretion. The two parallel gel channels in the 
middle are 600 × 180 μm (w × h) each, and the HUVEC/media channels by the side are 750 
× 180 μm (w × h). (B) The inset photograph of 3D projection represents an intact endothelial 
monolayer at the interface between the collagen and HUVEC channels in the device. 
Immunofluorescent staining for VE-cadherin (green in the image), a surface marker for 
endothelial cells, was routinely performed in our study to verify the integrity of HUVEC 
monolayer. (C) A list of 12 compounds tested in this study.
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Figure 2. 
(A) Representative images of A549 cancer spheroids before and after treatment with various 
compounds for 36 h. The cells were generated to stably express H2B-mCherry red 
fluorescence for visualization. (B) Quantitative analysis of the relative dispersion ratio of the 
spheroids. The relative dispersion rate of each sample group was determined and normalized 
to that in average of the control. Compounds 4 and 7 exhibited significant suppression of 
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spheroids dispersion. Data are expressed as Mean ± S.D (n=4). * P<0.01. (C) Comparison of 
the relative dispersion ratio of Compound 7 in different concentrations. (D) Representative 
images of the HUVECs pre-aligned along the channel after treatment with various 
compounds for 36 h (green for Calcein-AM staining), with Compound 2 causing obvious 
disruption to the endothelial layer.
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Figure 3. 
(A) The inhibitory effect of Compound 2 (sanguinarine chloride hydrate) on the viability of 
A549 and HUVEC cells in monolayer culture. Data are shown as Mean ± S.D (n=6). (B) 
Representative phase-contrast photographs of capillary tube formation of HUVECs on 
Matrigel and (C) Quantitative analysis of total tube length demonstrate that Compound 2 
effectively inhibits tube formation in a dose-dependent manner. Data are shown as Mean ± 
S.D (n=6).
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Figure 4. 
(A) The inhibitory effect of Compound 4 (nitidine chloride) on the viability of A549 and 
HUVEC cells in monolayer culture. Data are shown as Mean ± S.D (n=6). (B) 
Representative images of fluorescent Live/Dead staining of A549 multicellular cancer 
aggregates (MCAs) incubated with or without 13μM compound 4 after 24 h. (C) 
Representative photograph of agarose gel electrophoresis showing that Compound 4 
inhibited the activity of Topoisomerase I in relaxing supercoiled DNA.
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Figure 5. 
(A) The inhibitory effect of Compound 7 (resveratrol) on the viability of A549 and HUVEC 
cells in monolayer culture. Data are shown as Mean ± S.D (n=6). (B) The inhibitory effects 
of Compound 7 on the migration of A549 cells, which in m onolayer were scratched with a 
200 μl pipette tip and then incubated with Compound 7 (13.5 or 27 μM) and PMA (100nM) 
for 24 and 48 h. Photos were taken using a phase-contrast microscopy. (C) Quantitation of 
the scratch width at 0, 24, and 48 h.
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